0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Food and Drug Administration |

Two New Warnings Added to Labeling for Mibefradil

Stuart L. Nightingale, MD
JAMA. 1998;279(5):346. doi:10.1001/jama.279.5.346.
Text Size: A A A
Published online

Extract

The FDA is advising physicians about 2 new warnings in the labeling of mibefradil dihydrochloride (Posicor), a calcium channel blocker. One warning uses information from new reports to strengthen language in the labeling about the association between use of mibefradil and slowing or complete suppression of sinoatrial node activity. The supervening junctional rhythms have often been as slow as 30 to 40 beats per minute. Many of the reports have incorrectly identified the adverse event as complete AV block. The reports most commonly involved elderly patients, mainly in association with the concomitant use of β-blockers. Care should be taken when combining mibefradil with β-blockers. In patients with low heart rates, use of any combination of agents that can slow the sinus node or affect the AV node (eg, β-blockers, digitalis, and the calcium channel blockers mibefradil, diltiazem hydrochloride, and verapamil) should in general be undertaken only after careful consideration, as such combinations can unmask underlying sick sinus syndrome. Use of mibefradil in patients with sick sinus syndrome without a pacemaker is contraindicated.

Topics

mibefradil

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();